HLS Therapeutics (TSE:HLS) Stock Price Down 1.5% - Here's Why

HLS Therapeutics Inc. (TSE:HLS - Get Free Report) was down 1.5% on Tuesday . The stock traded as low as C$4.01 and last traded at C$4.06. Approximately 4,515 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 20,028 shares. The stock had previously closed at C$4.12.

Analyst Ratings Changes

Separately, Raymond James increased their price objective on HLS Therapeutics from C$4.00 to C$5.00 in a research note on Friday, November 22nd.

HLS Therapeutics Trading Down 1.5 %

The stock has a market capitalization of C$127.80 million, a PE ratio of -3.98 and a beta of 1.07. The company's 50 day moving average price is C$3.79 and its two-hundred day moving average price is C$3.54. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01.

HLS Therapeutics (TSE:HLS - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported C($0.20) earnings per share for the quarter, missing analysts' consensus estimates of C($0.19) by C($0.01). HLS Therapeutics had a negative return on equity of 24.82% and a negative net margin of 40.90%. During the same quarter in the previous year, the business earned ($0.28) earnings per share. As a group, analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.